FDA wants more da­ta from Abeona Ther­a­peu­tics as it push­es for BLA

Abeona Ther­a­peu­tics pushed back plans to sub­mit its gene ther­a­py for a rare skin con­di­tion af­ter the FDA asked the com­pa­ny for more da­ta about how the treat­ment is man­u­fac­tured.

The Cleve­land-based biotech said late last year that it planned to file its BLA in the sec­ond quar­ter of this year. But Abeona said Fri­day that it is re­quest­ing that a pre-BLA meet­ing date with the FDA be resched­uled for Au­gust fol­low­ing feed­back from the reg­u­la­tor. It now plans to sub­mit EB-101 in the third quar­ter of the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER